英国布里斯托大学孵化的AI生物科技初创公司CellVoyant宣布已经成功地筹集了760万英镑的种子资金。这家公司利用人工智能成像技术来帮助干细胞疗法开发商更加有效地生产新的治疗方法。
此次融资由Octopus Ventures领投，Horizons Ventures、Air Street Capital和Verve Ventures参投。这些投资者对CellVoyant的技术创新和市场潜力深感认同，并相信它将为全球生物医疗行业带来巨大的变革。
CellVoyant的创始人表示，这笔资金将主要用于进一步研发人工智能成像技术，以及扩大公司的市场份额和影响力。他们希望能够与更多的干细胞疗法开发商合作，共同推动新型疗法的研发和上市。
作为一家新兴的AI生物科技公司，CellVoyant已经引起了业内的广泛关注。它的技术创新和市场前景使其成为投资者眼中的香饽饽。未来，我们期待看到CellVoyant在生物科技领域的更多突破和发展。
英语如下：
Title: “Innovate Without Stopping! CellVoyant Secures £7.6M Seed Funding, AI Powers Stem Cell Therapy Development”
Keywords: CellVoyant, funding, artificial intelligence
Content: Title: AI Biotech Startup CellVoyant Successfully Raises £7.6M in Seed Funding
UK-based AI biotech startup CellVoyant, incubated by the University of Bristol, has announced that it has successfully raised £7.6 million in seed funding. The company utilizes artificial intelligence imaging technology to assist stem cell therapy developers in producing new treatments more effectively.
The financing round was led by Octopus Ventures with participation from Horizons Ventures, Air Street Capital, and Verve Ventures. These investors recognize CellVoyant’s technological innovation and market potential, believing it will bring about significant change for the global life sciences industry.
CellVoyant’s founders stated that the funds will primarily be used to further develop their artificial intelligence imaging technology as well as expand the company’s market share and influence. They hope to collaborate with more stem cell therapy developers to jointly advance the development and launch of novel therapies.
As an emerging AI biotech company, CellVoyant has already garnered widespread attention within the industry. Its technological innovation and market prospects make it an attractive investment opportunity for investors. Looking forward, we anticipate seeing more breakthroughs and developments from CellVoyant in the field of life sciences.
【来源】https://sifted.eu/articles/ai-biotech-cellvoyant-raise
Views: 1